A new trading day began on Tuesday, with Trevi Therapeutics Inc (NASDAQ: TRVI) stock price down -1.48% from the previous day of trading, before settling in for the closing price of $4.06. TRVI’s price has ranged from $1.27 to $4.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -67.24%. With a float of $52.99 million, this company’s outstanding shares have now reached $75.45 million.
In an organization with 25 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 40.71%, while institutional ownership is 35.34%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -67.24% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Here are Trevi Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.95 million. That was better than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.91%. Additionally, its Average True Range was 0.36.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 70.69%, which indicates a significant increase from 70.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 171.67% in the past 14 days, which was higher than the 89.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.15, while its 200-day Moving Average is $2.98. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $4.11. Second resistance stands at $4.23. The third major resistance level sits at $4.30. If the price goes on to break the first support level at $3.92, it is likely to go to the next support level at $3.85. The third support level lies at $3.73 if the price breaches the second support level.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
With a market capitalization of 357.46 million, the company has a total of 76,866K Shares Outstanding. Currently, annual sales are 0 K while annual income is -29,070 K. The company’s previous quarter sales were 0 K while its latest quarter income was -13,240 K.
